<DOC>
	<DOCNO>NCT00754403</DOCNO>
	<brief_summary>The purpose study determine efficacy pioglitazone metformin combination therapy , daily ( QD ) , glycosylated hemoglobin adult type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Pioglitazone Fortamet Combination Therapy Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>Pioglitazone ( ACTOS® ) member class oral antidiabetic agent know thiazolidinediones . The insulin-sensitizing action thiazolidinediones least partially mediate peroxisome proliferator-activated receptor gamma . These receptor find primarily adipocytes , vascular endothelial cell , monocyte , hepatocytes , less extent myocytes . Metformin develop extended-release formulation metformin hydrochloride design once-a-day oral administration . Metformin antihyperglycemic agent , improve glucose tolerance patient , type 2 diabetes , lower basal postprandial plasma glucose . On 15 July 1999 , FDA approve pioglitazone use adjunct diet exercise improve glycemic control patient type 2 diabetes . Pioglitazone indicate monotherapy use combination sulfonylurea , metformin , insulin diet exercise plus single agent result adequate glycemic control . On 26 November 2003 , FDA approve combined use pioglitazone metformin . This study design evaluate effect glycemic control pioglitazone metformin take together . Individuals participate study provide write informed consent require commit screen visit approximately 5 additional visit study center . Study participation anticipate 31 week ( approximately 8 month ) . Multiple procedure occur visit may include fasting , blood collection , urine collection , physical examination electrocardiograms .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion Criteria Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study Diagnosed type 2 diabetes must receive appropriate counseling lifestyle modification type 2 diabetes include diet exercise . If take metformin monotherapy metformin sulfonylurea combination therapy , glycosylated hemoglobin great equal 7.5 % less equal 9.0 % screen randomization . If naïve take sulfonylurea monotherapy glycosylated hemoglobin great equal 8.5 % less equal 10.0 % screen great equal 7.5 % less equal 9.0 % randomization . Exclusion Criteria Has type 1 diabetes mellitus Currently take thiazolidinedione take thiazolidinedione within 12 week prior screen Has congestive heart failure ; triglyceride level great 500 mg per dL Diastolic blood pressure great 100 mmHg systolic pressure great 160 mmHg Body mass index great equal 42 kg/m2 ( weight /height2 ) Alanine transaminase level great equal 2.5 time upper limit normal , active liver disease , jaundice . Male subject serum creatinine level great equal 1.5 mg per dL ; female subject serum creatinine level great equal 1.4 mg per dL screen visit randomization . Currently use insulin use insulin 3 month prior Screening Acute chronic metabolic acidosis , include diabetic ketoacidosis without coma . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Chronically use oral parenteral glucocorticoid ( eg , prednisone , cortisone , hydrocortisone , dexamethasone ) Niacin great 200 mg per day , include niacincontaining product Advicor 3 month prior screen study Chronically use steroidjoint injection 3 month prior screen study Thiazolidinediones 3 month prior screen study Insulin 3 month prior screen Other oral antidiabetic medication ( eg , nateglinide [ Starlix ] , acarbose [ Precose ] ) exception sulfonylurea 3 month prior screen study Metformin Fortamet Stabilization study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus , Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>